> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BMS Reports Positive Opdivo Results in CheckMate-648 Trial
- URL: https://www.fdaweb.com/bms-reports-positive-opdivo-results-in-checkmate-648-trial/
- Published: 2021-04-08T12:00:00.000Z
- Updated: 2026-09-14T16:54:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149069

Bristol Myers Squibb says there were positive topline results in the Phase 3 CheckMate-648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma. A company [statement](https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Announces-Opdivo-nivolumab-plus-Chemotherapy-and-Opdivo-plus-Yervoy-ipilimumab-Demonstrate-Superior-Survival-Benefit-Compared-to-Chemotherapy-in-Unresectable-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspx?ref=fdaweb.com) says that in the study Opdivo demonstrated a statistically significant and clinically meaningful benefit for the primary and secondary endpoints of overall survival in patients whose tumors express PD-L1 and in the all-randomized PD-L1.

Opdivo plus Yervoy met its primary and secondary endpoints by demonstrating statistically significant and clinically meaningful improvement in overall survival in patients whose tumors express PD-L1 and in the all-randomized population. Opdivo plus Yervoy did not meet its other primary endpoint of progression-free survival in patients whose tumors express PD-L1, the statement says.